Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Period	Debt/Equity
2021-12-31	0.12
2022-12-31	0.44
2023-12-31	0.41
2024-12-31	0.40

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RXRX	$3.17	+1.93%	5.86M
3
4
5

Recursion Pharmaceuticals Inc. (RXRX) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Recursion Pharmaceuticals Inc. Data in Excel

More RXRX Financial Data